ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel Dual-Target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Why It Matters

The findings address critical gaps in treatment options for EGFR exon‑20 insertion NSCLC and for ovarian/endometrial cancers, positioning ArriVent as a potential leader in these high‑unmet‑need segments.

Key Takeaways

• Firmonertinib binds both classical and exon20ins EGFR mutations
• Brain-penetrant EGFR inhibitor shows strong preclinical tumor suppression
• ARR-002 targets MUC16 and NaPi2b simultaneously
• Dual‑target ADC outperforms single‑target ADCs in xenograft models
• Favorable tolerability observed in cynomolgus monkey studies

Pulse Analysis

The emergence of exon‑20 insertion mutations as a driver of non‑small cell lung cancer has left clinicians with few effective oral options. Firmonertinib’s irreversible binding mode, combined with its ability to cross the blood‑brain barrier, differentiates it from first‑generation EGFR inhibitors that struggle with these atypical variants. Early preclinical data suggest that the compound can achieve sustained pathway suppression in both peripheral and central nervous system lesions, a critical advantage for patients at risk of brain metastases. This mechanistic breadth underpins the ongoing global Phase 3 trials that could reshape the standard of care for this molecularly defined cohort.

Antibody‑drug conjugates have historically suffered from target heterogeneity and limited payload delivery, leading to high attrition rates. ARR‑002 leverages ArriVent’s MUTTA™ platform to bind two tumor‑associated antigens—MUC16 and NaPi2b—on ovarian and endometrial cancer cells, effectively increasing the density of internalized drug‑antibody complexes. Preclinical xenograft studies report markedly improved tumor regression versus monovalent ADCs, while toxicology in cynomolgus monkeys indicates a wider therapeutic window. By addressing both antigen escape and payload distribution, the dual‑target design could set a new benchmark for next‑generation ADCs in solid tumors.

From an investor perspective, the simultaneous progression of a breakthrough EGFR inhibitor and a first‑in‑class dual‑target ADC diversifies ArriVent’s risk profile and expands its addressable market. Successful Phase 3 readouts for firmonertinib would unlock a sizable NSCLC segment, while early clinical data for ARR‑002 could attract partnership opportunities with larger oncology players seeking novel ADC platforms. The company’s strategic focus on structurally distinct, high‑impact modalities positions it to capture premium pricing and generate sustainable revenue streams once regulatory approvals are secured.